Farletuzumab (MORAb-003)

Farletuzumab (FAR) clinical studies are designed to investigate the safety and efficacy of farletuzumab in patients with folate receptor alpha (FRA) expressing tumors. FRA-expressing tumors under investigation include platinum-sensitive epithelial ovarian cancer and non-small cell lung adenocarcinoma.

For more information regarding FAR studies, please click here http://www.ClinicalTrials.gov/.

Current Studies

MORAb-003-011 Phase 2 Platinum-Sensitive Ovarian Cancer

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer.

For more information visit ClinicalTrials.gov. (Identifier: NCT02289950)

For more information about farletuzumab, please click here.

The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.